Position in PTGX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$192,940
+$27,041 QoQ
Shares Held
1,574
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#264
of 341 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KBC Group NV holds $308,329,109 across 107 Biotechnology names. PTGX ranks #37 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
179,508 | $111,930,417 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
128,466 | $63,812,914 | |
| 3 | INCY |
Incyte Corp
|
270,882 | $30,707,183 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
98,265 | $23,678,916 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
91,584 | $7,963,228 | |
| 6 | XENE |
Xenon Pharmaceuticals Inc.
|
129,010 | $7,787,043 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
127,194 | $7,278,040 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
116,847 | $6,372,835 |
All Filings in PTGX
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $192,940 | 1,574 | Shares | Defined | 2026-08-05 | |
| 2026-03-31 | $165,899 | 1,574 | Shares | Defined | 2026-05-07 | |
| 2025-12-31 | $137,473 | 1,574 | Shares | Defined | 2026-01-26 | |
| 2025-09-30 | $104,560 | 1,574 | Shares | Defined | 2026-01-20 | |
| 2025-06-30 | $86,994 | 1,574 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | $101,217 | 2,093 | Shares | Defined | 2025-04-25 | |
| 2024-12-31 | $80,789 | 2,093 | Shares | Defined | 2025-01-22 | |
| 2024-09-30 | $61,020 | 1,356 | Shares | Defined | 2024-11-06 | |
| 2024-06-30 | $46,985 | 1,356 | Shares | Defined | 2024-07-17 | |
| 2024-03-31 | $34,773 | 1,202 | Shares | Defined | 2024-05-08 | |
| No filing history on record for this holder in this stock. | ||||||